You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
A potent blocker of glutamate transport; selective for EAAT2 and EAAT4 (IC50 values are 90, 109, 1600 and 1080 μM for EAAT2, EAAT4, EAAT1 and EAAT3 respectively).
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 161.16. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||6.21 mL||31.03 mL||62.05 mL|
|5 mM||1.24 mL||6.21 mL||12.41 mL|
|10 mM||0.62 mL||3.1 mL||6.21 mL|
|50 mM||0.12 mL||0.62 mL||1.24 mL|
References are publications that support the biological activity of the product.
Eliasof et al (2001) Pharmacological characterization of threo-3-methylglutamic acid with excitatory amino acid transporters in native and recombinant systems. J.Neurochem. 77 550 PMID: 11299317
Mitrovic et al (1998) Identification of functional domains of the human glutamate transporters EAAT1 and EAAT2. J.Biol.Chem. 273 14698 PMID: 9614067
Vandenberg et al (1997) Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2. Mol.Pharmacol. 51 809 PMID: 9145919
If you know of a relevant reference for (±)-threo-3-Methylglutamic acid, please let us know.
View Related Products by Product Action
Keywords: (±)-threo-3-Methylglutamic acid, (±)-threo-3-Methylglutamic acid supplier, EAAT2, EAAT4, blockers, Excitatory, Amino, Acid, Transporters, GLT-1, Glutamate, Monoamine, Neurotransmitter, 0811, Tocris Bioscience
1 Citation for (±)-threo-3-Methylglutamic acid
Citations are publications that use Tocris products. Selected citations for (±)-threo-3-Methylglutamic acid include:
Jarzylo and Man (2012) Parasynaptic NMDA receptor signaling couples neuronal glutamate transporter function to AMPA receptor synaptic distribution and stability. J Neurosci 32 2552 PMID: 22396428
Do you know of a great paper that uses (±)-threo-3-Methylglutamic acid from Tocris? Please let us know.
Reviews for (±)-threo-3-Methylglutamic acid
There are currently no reviews for this product. Be the first to review (±)-threo-3-Methylglutamic acid and earn rewards!
Have you used (±)-threo-3-Methylglutamic acid?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.